CAR T cell News and Research

RSS

UCSF researchers discover a new way to control immune system's 'natural killer' cells

UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection.

8 Jan 2021

NCCN publishes new informational resources on health and wellness for cancer survivors

Today, the National Comprehensive Cancer Network announced the publication of new, free informational resources on health and wellness for cancer survivors.

5 Jan 2021

New cell therapy can boost immunotherapy against breast cancer

Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center.

4 Jan 2021

Scientists demonstrate a promising strategy for treating lymphomas

Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes.

16 Dec 2020

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity

Cancer immunotherapy using "designer" immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient's blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells.

14 Dec 2020

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

7 Dec 2020

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

7 Dec 2020

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

Genetically engineered T cells can target, attack pathogenic T cells that cause Type 1 diabetes

A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.

3 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Penn study opens the door to let CAR T cells reach the tumor microenvironment

The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors.

30 Nov 2020

Combining cell engineering with machine learning to design living medicines for cancer

Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.

26 Nov 2020

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.

25 Nov 2020

PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.

From PhoreMost 10 Nov 2020

A new method to improve the preclinical evaluation of CAR T cell therapies

Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system's T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment.

6 Nov 2020

Radiation therapy before CART-BCMA appears to be a safe option for multiple myeloma patients

Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania to be presented Tuesday, October 27, at the virtual American Society for Radiation Oncology Annual Meeting (Abstract #35562).

27 Oct 2020

Novel microfluidic approach to fight cancer could greatly benefit patients

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

20 Oct 2020

A global review of COVID-19 impact on cancer treatment and research

The COVID-19 pandemic has impacted virtually every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows.

7 Oct 2020

CAR T cell News and Research

UCSF researchers discover a new way to control immune system's 'natural killer' cells

NCCN publishes new informational resources on health and wellness for cancer survivors

New cell therapy can boost immunotherapy against breast cancer

Scientists demonstrate a promising strategy for treating lymphomas

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Genetically engineered T cells can target, attack pathogenic T cells that cause Type 1 diabetes

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Penn study opens the door to let CAR T cells reach the tumor microenvironment

Combining cell engineering with machine learning to design living medicines for cancer

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies

A new method to improve the preclinical evaluation of CAR T cell therapies

Radiation therapy before CART-BCMA appears to be a safe option for multiple myeloma patients

Novel microfluidic approach to fight cancer could greatly benefit patients

A global review of COVID-19 impact on cancer treatment and research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News